Xenetic Biosciences, Inc. (XBIO)
| Market Cap | 6.94M +57.8% |
| Revenue (ttm) | 3.19M +23.5% |
| Net Income | -2.23M |
| EPS | -1.18 |
| Shares Out | 2.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,111 |
| Open | 3.085 |
| Previous Close | 3.110 |
| Day's Range | 2.978 - 3.140 |
| 52-Week Range | 1.900 - 13.930 |
| Beta | 2.22 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 12, 2026 |
About XBIO
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company’s product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the tr... [Read more]
Financial Performance
In 2025, Xenetic Biosciences's revenue was $2.98 million, an increase of 19.04% compared to the previous year's $2.50 million. Losses were -$2.68 million, -32.31% less than in 2024.
Financial StatementsNews
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
Advancements across investigator-initiated studies, translational research and manufacturing activities supporting future clinical development Strengthened financial profile with continued royalty rev...
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
FRAMINGHAM, MA / ACCESS Newswire / April 22, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology te...
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results
Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat cancers Strategic focus on investigator-initiated exploratory studies and institut...
Xenetic Biosciences Transcript: AGM 2025
The meeting was called to order with auditors and legal counsel present, but a quorum was not reached, preventing any business from being conducted. The board will set a new date for the adjourned meeting.
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting
Adjourns 2025 Annual Meeting of Stockholders Urges Stockholders Who Have Not Voted To Get Votes In FRAMINGHAM, MA / ACCESS Newswire / December 11, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xene...
Xenetic extends R&D collaboration with The Scripps Research Institute
Xenetic (XBIO) Biosciences executed a 4-month extension of its collaboration with The Scripps Research Institute and the lab of Dr. Alexey Stepanov, Institute Investigator at Scripps Research effectiv...
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform
FRAMINGHAM, MA / ACCESS Newswire / November 19, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology...
Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results
Continued execution on collaborations and exploratory investigator-initiated studies with institutional partners Secured net proceeds of approximately $3.9 million from October 2025 offering FRAMINGHA...
Xenetic Biosciences trading resumes
11:16 EDT Xenetic (XBIO) Biosciences trading resumes
Xenetic Biosciences trading halted, volatility trading pause
11:06 EDT Xenetic (XBIO) Biosciences trading halted, volatility trading pause
Xenetic 735,000 share Spot Secondary priced at $6.12
Xenetic (XBIO) Biosciences announced the pricing of an underwritten offering of 735,000 shares of common stock at a price to the public of $6.12 per share, for gross proceeds of…
Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock
FRAMINGHAM, MA / ACCESS Newswire / October 10, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology ...
Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results
Expanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studies and further develop its program combining systemic DNase I with CAR T-cell therapies Ended the qu...
Xenetic says PeriNess enters clinical study agreement for DNase Platform
Xenetic (XBIO) Biosciences announced that its collaboration partner, PeriNess, has entered into a Clinical Study Agreement to support an exploratory clinical study of DNase I in combination with anti-...
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma
Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center FRAMINGHAM, MA / ACCESS Newswire / July 30, 2025 / Xenetic Biosciences, Inc. ...
Xenetic expands collaboration with The Scripps Research Institute
Xenetic (XBIO) Biosciences has continued its collaboration with The Scripps Research Institute to advance the development of the Company’s development program evaluating the combination of systemic DN...
Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Research and development collaboration program to include additional models of lymphoma and leukemia to further validate DNase-I data demonstrated to date FRAMINGHAM, MA / ACCESS Newswire / July 23, 2...
Xenetic says PeriNess reports Bnei Zion Medical Center commences patient dosing
Xenetic (XBIO) Biosciences announced that its collaboration partner, PeriNess, has informed the Company that Bnei Zion Medical Center has commenced patient dosing in an exploratory clinical study of s...
Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Investigator initiated exploratory clinical study being conducted in Israel pursuant to agreement with collaboration partner, PeriNess Company evaluating systemic recombinant human DNase I (DNase I) i...
Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
Strategic focus on exploratory investigator-initiated clinical studies with institutional partners Continued progress of DNase I development program towards IND and first-in-human study for treatment ...
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
- Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (S...
Xenetic partner PeriNess enters clinical study agreement for XBIO-015
Xenetic (XBIO) Biosciences’ collaboration partner, PeriNess has entered into a Clinical Study Agreement to support an exploratory clinical study of Xenetic’s systemic DNase I candidate, XBIO-015, in p...
Xenetic: PeriNess in XBIO-015 study to treat osteosarcoma and Ewing sarcoma
Xenetic (XBIO) Biosciences, announced that its collaboration partner, PeriNess has entered into a Clinical Study Agreement to support an exploratory clinical study of Xenetic’s systemic DNase I candid...
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma
Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center FRAMINGHAM, MA / ACCESS Newswire / March 26, 2025 / Xenetic Biosciences, Inc....
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results
Encouraging preclinical data supporting the use of DNase-based technology to target NETosis and address difficult to treat cancers Strategic focus on exploratory investigator-initiated clinical studie...